Leaflet NOPREX 52.5mcg / h transdermal patch


Indicated for: severe pain; opioid dependence

Route of administration: transdermal

Substance: buprenorphine (opioid analgesic)

ATC: N02AE01 (Nervous system | Opioids | Oripavine derivatives)

Precautions:
Driving impairment
Driving impairment

This medicine may affect your ability to drive or use machines.

Dizziness / vertigo
Dizziness / vertigo

This medicine may cause dizziness or vertigo.

Dependence / abuse
Dependence / abuse

This medicine may cause dependence or be misused.

Respiratory depression
Respiratory depression

May slow breathing, especially with alcohol or sedatives.

Avoid alcohol
Avoid alcohol

Avoid alcohol during treatment.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Elderly warning
Elderly warning

Older people may have an increased risk of side effects.

Withdrawal / do not stop abruptly
Withdrawal / do not stop abruptly

Do not stop treatment abruptly without medical advice.

Drowsiness / sedation
Drowsiness / sedation

This medicine may cause drowsiness or reduced alertness.

Buprenorphine is an opioid analgesic used for the treatment of moderate to severe pain and for managing opioid dependence. It is a partial agonist of mu-opioid receptors and an antagonist of kappa-opioid receptors, providing strong analgesic effects with a lower risk of respiratory depression compared to other opioids.

The medication is available in the form of sublingual tablets, transdermal patches, or injections, and the dosage is adjusted based on the severity of pain or the patient's needs in opioid dependence treatment.

Common side effects include nausea, constipation, dizziness, drowsiness, and excessive sweating. In rare cases, more severe adverse effects such as severe respiratory depression or allergic reactions may occur.

Buprenorphine is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions. Additionally, the use of this medication requires careful medical supervision to prevent abuse, dependence, or other complications associated with opioids.

General data about NOPREX 52.5mcg / h

  • Substance: buprenorphine
  • Date of last drug list: 01-03-2026
  • Commercial code: W62650001
  • Concentration: 52.5mcg / h
  • Pharmaceutical form: transdermal patch
  • Quantity: 4
  • Product type: generic
  • Prescription restrictions: TAB3 - Medicines that are issued with a special prescription (psychotropic) in green color.

Pharmaceutical forms available for buprenorphine

Concentrations available for buprenorphine

  • 0.4mg
  • 2mg
  • 35mcg/h
  • 52.5mcg/h
  • 70mcg/h
  • 74.2mg
  • 8mg

Combinations with other substances